Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 MLN8237 in platinum-refractory or -resistant ovarian, fallopian tube, or primary peritoneal carcinoma
2008-006979-72Phase 2Completed
- Sponsor
- Millennium Pharmaceuticals, Inc
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alisertib in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Millennium Pharmaceuticals, Inc. Primary endpoint: Combined objective response rate. Started Mar 2009; status: completed.
02
Drugs
alisertib
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2008-006979-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006979-72.